Indivior PLC

Regulatory Filings • May 20, 2020

National Storage Mechanism | Additional information

RNS Number : 5129N

Indivior PLC

20 May 2020

Indivior to Participate in Jefferies Virtual Healthcare Conference

Slough, UK and Richmond, VA - May 20, 2020 - Indivior PLC (LON: INDV) today announced that Shaun Thaxter, Chief Executive Officer, and Mark Crossley, Chief Financial & Operations Officer, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2020. Please contact your Jefferies representative to request a meeting.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

Contact:

Jason Thompson

804-402-7123

Vice President, Investor Relations

jason.thompson@indivior.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCEAASEADPEEFA